[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"intrauterine-abnormalities-in-infertility\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:intrauterine-abnormalities-in-infertility":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":31,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":5},"100605303","safety-and-performance-of-the-semical-adhesion-barrier-gel-for-prevention-of-intra-uterine-adhesion-100605303",false,"NCT07160764","Safety and Performance of the Semical Adhesion Barrier Gel for Prevention of Intra-uterine Adhesion","Evaluation of Performance and Safety of Hyalosem Cross-linked Hyaluronic Acid Adhesion Barrier Gel in Preventing Intra-uterine Adhesion Formation After Operative Hysteroscopy: A Retrospective Study","SEMFERTIL","Inclusion Criteria:\n\n* Female patients aged 18 and over\n* Patients who were treated with operative hysteroscopy for intrauterine pathology (endometrial polips, myomas with uterine cavity deformation, uterine septa, intrauterine adhesion, ovarian cyst, endometrial cyst, etc.)\n* Patients who had undergone operative hysteroscopy at least 30 days and at most 6 months ago\n* Patients who had second-look office hysteroscopy at least once after an operative hysteroscopy\n\nExclusion Criteria:\n\n* Children and adolescents under 18 years of age\n* Having a body weight of more than 100 kg\n* Surgeries complicated by excessive bleeding; estimated blood loss of more than 100 cc\n* Surgeries complicated with uterine perforation\n* Presence of uncontrolled diabetes, coagulation disorders, and other severe chronic disorders\n* Presence of malignant tumor or diagnosis of cancer, presence of uterovaginal prolapse\n* Concomitant peritoneal grafting or tubal implantation\n* Concomitant intrauterine device implantation\n* Patients without second-look hysteroscopy\n\nAccording to the GDPR and clinical investigation legislation, written informed consent is not mandatory in retrospective studies as long as the patient's personal information is censored.",true,"FEMALE","18 Years",{"count":21,"type":22},80,"ESTIMATED","OBSERVATIONAL","The aim of this study was to obtain short- and long-term performance and safety data of cross-linked hyaluronic acid-based adhesion barrier gel used to prevent intrauterine adhesion formation.",[26,27,28,29,30],"Intrauterine Abnormalities in Infertility","Asherman Syndrome","Intra-uterine Adhesions","Postoperative Adhesion of Uterus","Asherman's Syndrome",[32,33,34,35],"intrauterine abnormalities","asherman's syndrome","intrauterine adhesions","postoperative adhesions","NOT_YET_RECRUITING","2025-09-01",{"date":39,"type":40},"2025-09-08","ACTUAL",{"date":42,"type":22},"2025-11-01",{"date":44,"type":22},"2025-12-31",{"name":46,"class":47},"Semikal Technology","INDUSTRY"]